An oral formulation of gold for the treatment of rheumatoid arthritis.

Twenty-two patients with active rheumatoid arthritis were entered into a trial during which an oral gold formulation was administered at two dosages (4 mg/d and 6 mg/d) for 12 weeks. Seventeen patients completed the trial. Both dosages produced a similar improvement in the indices of inflammation. Five patients were not benefited by the treatment, adverse side-effects were reported in 10 and 5 were withdrawn from the trial.

RCT Entities:   Population Interventions Outcomes